Privium Fund Management B.V. Purchases 2,850 Shares of Krystal Biotech, Inc. $KRYS

Privium Fund Management B.V. increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 30.6% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,170 shares of the company’s stock after purchasing an additional 2,850 shares during the period. Krystal Biotech makes up about 0.4% of Privium Fund Management B.V.’s holdings, making the stock its 29th biggest holding. Privium Fund Management B.V.’s holdings in Krystal Biotech were worth $2,148,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in KRYS. Hantz Financial Services Inc. raised its holdings in shares of Krystal Biotech by 8,950.0% during the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after acquiring an additional 179 shares in the last quarter. AdvisorNet Financial Inc purchased a new stake in Krystal Biotech in the third quarter worth about $30,000. Salomon & Ludwin LLC bought a new position in Krystal Biotech during the 3rd quarter valued at approximately $33,000. First Horizon Advisors Inc. increased its holdings in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Finally, Caldwell Trust Co purchased a new position in Krystal Biotech in the second quarter worth about $34,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS opened at $279.24 on Friday. The stock has a market cap of $8.10 billion, a price-to-earnings ratio of 41.87 and a beta of 0.46. The firm’s fifty day moving average is $251.19 and its 200 day moving average is $196.77. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $295.98.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analyst Ratings Changes

KRYS has been the topic of a number of research analyst reports. Chardan Capital upped their price target on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Citigroup lifted their price target on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Zacks Research upgraded shares of Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $277.89.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.70% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.